SG11201608608PA - Rapid relief of motor fluctuations in parkinson's disease - Google Patents

Rapid relief of motor fluctuations in parkinson's disease

Info

Publication number
SG11201608608PA
SG11201608608PA SG11201608608PA SG11201608608PA SG11201608608PA SG 11201608608P A SG11201608608P A SG 11201608608PA SG 11201608608P A SG11201608608P A SG 11201608608PA SG 11201608608P A SG11201608608P A SG 11201608608PA SG 11201608608P A SG11201608608P A SG 11201608608PA
Authority
SG
Singapore
Prior art keywords
parkinson
disease
rapid relief
motor fluctuations
fluctuations
Prior art date
Application number
SG11201608608PA
Inventor
Richard P Batycky
Martin Freed
Michael M Lipp
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of SG11201608608PA publication Critical patent/SG11201608608PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SG11201608608PA 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease SG11201608608PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/034778 WO2015163840A1 (en) 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease

Publications (1)

Publication Number Publication Date
SG11201608608PA true SG11201608608PA (en) 2016-11-29

Family

ID=54332876

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608608PA SG11201608608PA (en) 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease

Country Status (14)

Country Link
US (2) US20170296498A1 (en)
EP (2) EP3831375A1 (en)
JP (1) JP2017513866A (en)
KR (2) KR20210144946A (en)
CN (2) CN113209055A (en)
AU (2) AU2014391721B2 (en)
BR (1) BR112016024502A8 (en)
CA (1) CA2946165C (en)
IL (2) IL309959A (en)
MX (1) MX2016013741A (en)
RU (1) RU2698330C2 (en)
SG (1) SG11201608608PA (en)
WO (1) WO2015163840A1 (en)
ZA (1) ZA201607833B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015010601B1 (en) 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOSITION
JP2021509676A (en) * 2018-01-05 2021-04-01 インペル ニューロファーマ インコーポレイテッド Intranasal delivery of levodopa powder by precision olfactory device
JP2021532098A (en) 2018-07-19 2021-11-25 インペル ニューロファーマ インコーポレイテッド Respiratory tract delivery of levodopa and dopa decarboxylase inhibitors for the treatment of Parkinson's disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
ES2609482T3 (en) * 2002-03-20 2017-04-20 Civitas Therapeutics, Inc. Lung administration of levodopa
AR044007A1 (en) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
WO2008156586A2 (en) 2007-06-12 2008-12-24 Alkermes, Inc. Inhalation device for powdered substances
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
CA2729595C (en) * 2008-06-30 2017-01-03 Novartis Ag Combinations comprising mglur modulators for the treatment of parkinson's disease
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
TW201304822A (en) * 2010-11-15 2013-02-01 Vectura Ltd Compositions and uses
JP2016500690A (en) * 2012-10-22 2016-01-14 サイヴィタス セラピューティックス,インコーポレイテッド Levodopa formulation for rapid relief of Parkinson's disease
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use

Also Published As

Publication number Publication date
EP3134077A4 (en) 2017-12-20
EP3831375A1 (en) 2021-06-09
EP3134077A1 (en) 2017-03-01
ZA201607833B (en) 2018-08-29
WO2015163840A1 (en) 2015-10-29
IL248445A0 (en) 2016-12-29
MX2016013741A (en) 2017-04-06
IL309959A (en) 2024-03-01
US20230053976A1 (en) 2023-02-23
CA2946165C (en) 2022-10-18
KR20210144946A (en) 2021-11-30
AU2020239754A1 (en) 2021-01-14
RU2016144340A (en) 2018-05-22
BR112016024502A2 (en) 2017-08-15
AU2014391721A1 (en) 2016-11-03
RU2016144340A3 (en) 2018-05-22
CA2946165A1 (en) 2015-10-29
RU2698330C2 (en) 2019-08-26
AU2014391721B2 (en) 2020-07-16
US20170296498A1 (en) 2017-10-19
CN113209055A (en) 2021-08-06
AU2020239754B2 (en) 2022-06-23
JP2017513866A (en) 2017-06-01
CN106659685B (en) 2021-02-05
BR112016024502A8 (en) 2021-06-29
KR20170008754A (en) 2017-01-24
CN106659685A (en) 2017-05-10

Similar Documents

Publication Publication Date Title
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
IL280530A (en) Aadc polynucleotides for the treatment of parkinson's disease
PL3157512T3 (en) Use of cannabidiol in the treatment of epilepsy
GB201418170D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418166D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418169D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
PL2968218T3 (en) Combination for the treatment of parkinson's disease
IL246999A0 (en) Methods of treating alzheimer's disease
SG11201702819YA (en) Skin cosmetic
PL3277280T3 (en) Isomyosmine for use in the treatment of autoimmune diseases
IL263188B (en) Treatment for parkinson's disease
GB201417163D0 (en) Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
EP3177304A4 (en) Therapeutic nanoparticles for accumulation in the brain
GB201418172D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
EP3217973A4 (en) Melatonin in autoimmune disease
ZA201607833B (en) Rapid relief of motor fluctuations in parkinson's disease
GB2553527B (en) Headgear suitable for use in hydrotherapy
EP3109636A4 (en) Biomarker for parkinson's disease and use therefor
ZA201807944B (en) Treatment for parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment
HK1220029A1 (en) Improvements in and relating to imaging of the eye
GB201504144D0 (en) Treatment of Parkinson's disease
GB201414038D0 (en) Alzheimer's disease
GB201418079D0 (en) Eye care accessories
GB201410695D0 (en) Uses of oligouronates in cancer treatment